From the aspect of clinical value, a meta-analysis has demonstrated that BUB1B was a significant biomarker for a poor prognosis and poor clinicopathological outcomes in patients with lung adenocarcinoma 14. Here, BUB1B is linked to lung adenocarcinoma.